Epidemiology — MCQs

In a developing country, the prevalence of diabetes mellitus is increasing at an annual rate of 1.8%. Using epidemiological principles similar to the Rule of 70, approximately how many years will it take for the diabetes prevalence to double, and what are the primary healthcare planning implications of this growth rate?

Q1786

Randomization is done to reduce?

Q1787

Which of the following statements about incidence is false?

Q1788

Which statement best describes the concept of web of causation in disease?

Q1789

What does the term 'proportional mortality rate' refer to?

Q1790

Which study design is primarily used to understand the natural history of a disease?

Epidemiology Indian Medical PG Practice Questions and MCQs

Question 1781: Which of the following diseases is not covered under the Integrated Disease Surveillance Project (IDSP)?

A. Tuberculosis
B. Cholera
C. Herpes zoster (Correct Answer)
D. Meningococcal disease

Explanation: ***Herpes zoster*** - **Herpes zoster** (shingles) is not included in the Integrated Disease Surveillance Project (IDSP) as it is neither an epidemic-prone disease nor a notifiable disease under the program. - IDSP focuses on diseases with significant public health impact, epidemic potential, or those requiring immediate public health response. - While herpes zoster can cause morbidity in immunocompromised individuals, it does not pose a widespread public health threat requiring national surveillance. *Tuberculosis* - **Tuberculosis (TB)** is explicitly covered under IDSP as a major notifiable disease due to its high burden in India and significant public health importance. - TB surveillance under IDSP helps monitor disease trends, detect outbreaks, and evaluate the effectiveness of the National Tuberculosis Elimination Programme. - Regular reporting and surveillance are essential for achieving TB elimination goals. *Cholera* - **Cholera** is a priority disease under IDSP as an epidemic-prone disease with potential for rapid outbreaks and high mortality if untreated. - It is part of the core surveillance list due to its ability to cause severe dehydration and waterborne epidemics. - Early detection through IDSP enables timely implementation of control measures including safe water supply and oral rehydration therapy. *Meningococcal disease* - **Meningococcal disease** (acute bacterial meningitis) is covered under IDSP due to its high case fatality rate, epidemic potential, and need for urgent public health response. - Surveillance is critical for early outbreak detection and implementation of preventive measures such as mass vaccination and chemoprophylaxis. - Close monitoring helps identify circulating serotypes and guide vaccination strategies.

Question 1782: When is screening for breast cancer recommended?

A. When the disease has a low case fatality rate
B. When diagnostic tools are available
C. When no effective treatment is available
D. When early diagnosis can change the disease course due to effective treatment (Correct Answer)

Explanation: ***When early diagnosis can change the disease course due to effective treatment*** - **Screening** for cancer, like breast cancer, is most beneficial when early detection allows for interventions that effectively alter the disease's natural progression, leading to better outcomes. - The availability of **effective treatments** is a cornerstone for recommending screening programs, as finding a disease early without the means to treat it effectively offers little patient benefit. *When the disease has a low case fatality rate* - Diseases with a **low case fatality rate** are generally less urgent candidates for widespread screening, as the potential benefit of early detection is diminished if the disease is not often fatal. - Screening is more commonly applied to diseases with **significant morbidity and mortality**, where early intervention can make a substantial difference. *When diagnostic tools are available* - While the availability of **diagnostic tools** is a prerequisite for screening, it is not the sole determinant for recommending a screening program. - The diagnostic tools must also be **accurate, safe, and cost-effective**, and their use must lead to improved patient outcomes through early intervention. *When no effective treatment is available* - If **no effective treatment** is available, screening for a disease can cause more harm than good due to the psychological burden of diagnosis without the possibility of intervention. - In such cases, screening is generally not recommended, as it does not improve **patient prognosis** or quality of life.

Question 1783: In the context of disease screening, which type of lead time is most beneficial for effective screening?

A. Short lead time
B. Both short and long lead times are beneficial
C. Long lead time is beneficial for screening (Correct Answer)
D. Lead time has no impact on screening effectiveness

Explanation: ***Long lead time is beneficial for screening*** - **Long lead time** provides a greater window of opportunity between disease detection by screening and clinical symptom onset - This extended asymptomatic detectable phase allows for **early intervention** when treatments are most effective - Longer lead time correlates with improved prognosis and potential prevention of severe outcomes - Essential criterion for effective screening programs per **Wilson-Jungner criteria** *Short lead time* - Limited time between disease detectability and clinical symptoms - Reduces screening effectiveness as disease progresses rapidly - Minimal opportunity for beneficial early intervention *Both short and long lead times are beneficial* - Only **long lead time** is beneficial for screening programs - Short lead time actually limits screening effectiveness - Screening benefit is directly proportional to duration of asymptomatic detectable phase *Lead time has no impact on screening effectiveness* - **Lead time is crucial** for determining screening program effectiveness - Directly impacts the window for early detection and intervention - Without adequate lead time, screening loses its preventive value

Question 1784: What is the descending order of cancer incidence among males globally for the following cancer types?

A. Pharynx > lung > oral > esophagus
B. Esophagus > oral > stomach > lung
C. Oral > lung > pharynx > esophagus
D. Lung > oral > pharynx > esophagus (Correct Answer)

Explanation: ***Oral > lung > pharynx > esophagus*** - This sequence accurately reflects the **prevalence rates** of cancers among males [1], with **oral cancer** notably high in certain regions. - **Lung cancer** follows as the second most prevalent due to risk factors like **smoking** and air pollution [1]. *Lung > oral > pharynx > esophagus* - While lung cancer is indeed common, this order is incorrect as it **underestimates oral cancer**, which is highly prevalent in specific populations. - The ranking does not reflect **regional variations** in cancer prevalence, particularly in areas with high oral cancer rates. *Esophagus > oral > stomach > lung* - This order inaccurately places **esophageal cancer** above oral cancer, failing to account for the high prevalence of oral cancers in many regions. - The statement does not align with common epidemiological data that shows **lung cancer preeminence** in general male populations [1]. *Pharynx > lung > oral > esophagus* - This incorrect sequence ranks pharyngeal cancer too high, ignoring the more **established prevalence** of oral and lung cancers. - The order does not reflect the understanding that **lung cancer** remains one of the leading cancers among men [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 284-286.

Question 1785: In a developing country, the prevalence of diabetes mellitus is increasing at an annual rate of 1.8%. Using epidemiological principles similar to the Rule of 70, approximately how many years will it take for the diabetes prevalence to double, and what are the primary healthcare planning implications of this growth rate?

A. 30-35 years
B. 35-46 years (Correct Answer)
C. 25-30 years
D. 20-25 years

Explanation: ***35-46 years*** - Using the **Rule of 70**, divide 70 by the annual growth rate (1.8%): 70 / 1.8 ≈ **38.89 years**. This value falls within the 35-46 year range. - The doubling of diabetes prevalence within this timeframe necessitates significant **healthcare planning implications**, including increased demand for diagnostic services, medications, and specialized care, as well as focused preventative measures. *30-35 years* - This range is too low, as the calculated doubling time of approximately **38.89 years** is longer than this range. While close, this timeframe underestimates the actual time needed for prevalence to double. *25-30 years* - This range is significantly lower than the calculated doubling time of approximately **38.89 years**, meaning it underestimates the time required for diabetes prevalence to double by about 9-14 years. *20-25 years* - This range is far too low, as the calculated doubling time of approximately **38.89 years** is much longer. This timeframe would suggest a much higher annual growth rate than the stated 1.8%.

Question 1786: Randomization is done to reduce?

A. Recall bias
B. Selection bias (Correct Answer)
C. Berksonian bias
D. Reporting bias

Explanation: ***Selection bias*** - **Randomization** ensures that each participant has an equal chance of being assigned to any study group, which helps to distribute both known and unknown confounding factors evenly. - This process minimizes **selection bias** by promoting comparability between groups, making it more likely that any observed differences are due to the intervention rather than pre-existing differences. *Recall bias* - **Recall bias** occurs when there are systematic differences in the way participants remember or report past exposures or events, often seen in retrospective studies. - While randomization helps control for confounding, it does not directly prevent participants from inaccurately recalling information. *Berksonian bias* - **Berksonian bias** is a form of selection bias where the probability of being admitted to a hospital (or selected into a study) is affected by the presence of a co-morbidity, leading to a distorted association between diseases. - Randomization aims to balance characteristics *within* the study groups once participants are recruited, but it doesn't address biases related to the initial selection into the study population from a larger source. *Reporting bias* - **Reporting bias** refers to selective revealing or suppression of information, either by study participants (e.g., social desirability bias) or by researchers (e.g., only reporting positive findings). - Randomization helps ensure internal validity by creating comparable groups, but it does not prevent individuals from selectively reporting outcomes or experiences.

Question 1787: Which of the following statements about incidence is false?

A. Does not include unit of time (Correct Answer)
B. It is a rate
C. Numerator includes new cases
D. Denominator includes population at risk

Explanation: ***Does not include unit of time*** - This statement is false because **incidence** is defined as the number of **new cases** of a disease over a specific period of time in a population at risk. - Therefore, it inherently includes a **unit of time** (e.g., per year, per month), making this option incorrect as a characteristic of incidence. *It is a rate* - **Incidence is a rate** because it quantifies the speed at which new cases of a disease occur within a population. - It expresses the number of new events (cases) per unit of population at risk over a specified time period. *Numerator includes new cases* - The **numerator of incidence** specifically counts the number of **new cases** of a disease that develop during a defined observation period. - This distinguishes it from prevalence, which includes all existing cases. *Denominator includes population at risk* - The **denominator for incidence** comprises the **population at risk** of developing the disease during the observation period. - Individuals who already have the disease or are immune are typically excluded from the denominator.

Question 1788: Which statement best describes the concept of web of causation in disease?

A. Applicable primarily to common diseases.
B. Focuses on epidemiological ratios.
C. Aids in interrupting the transmission of diseases.
D. Considers all relevant factors associated with disease causation. (Correct Answer)

Explanation: ***Considers all relevant factors associated with disease causation.*** - The **web of causation** model acknowledges that diseases often arise from a complex interplay of multiple interconnected factors, rather than a single cause. - It emphasizes that **no single factor is sufficient or necessary** for disease occurrence, but rather a combination of factors increases susceptibility or triggers the disease process. *Applicable primarily to common diseases.* - The web of causation model is a **universal concept** in epidemiology, applicable to both common and rare diseases. - Its utility lies in explaining the complex etiology of diseases regardless of their prevalence. *Focuses on epidemiological ratios.* - While epidemiological ratios (e.g., odds ratios, relative risk) measure associations between factors and disease, the **web of causation** provides a conceptual framework for understanding the *nature* of these associations. - It describes the **interconnections and causal pathways**, not just the statistical strength of association. *Aids in interrupting the transmission of diseases.* - This statement is more descriptive of **public health interventions** based on understanding disease transmission dynamics. - While insights from the **web of causation** can inform interventions, the model itself describes the *etiology* rather than directly outlining methods for interrupting transmission.

Question 1789: What does the term 'proportional mortality rate' refer to?

A. The total number of deaths in a given year
B. The number of deaths in a specific month
C. The total number of deaths regardless of cause
D. The proportion of deaths due to a specific cause in relation to total deaths (Correct Answer)

Explanation: ***The proportion of deaths due to a specific cause in relation to total deaths*** - The **proportional mortality rate** calculates the fraction of all deaths in a population attributable to a particular cause. - This metric helps to understand the relative importance of specific diseases or conditions as causes of death within a given period. *The total number of deaths in a given year* - This option describes the **crude death count** or **absolute number of deaths**, not a proportional rate. - It does not provide information about the **distribution** or **proportion** of deaths due to specific causes. *The number of deaths in a specific month* - This refers to a **monthly death count**, which is a measure of absolute frequency over a shorter period. - It does not represent a **proportion** of specified deaths compared to total deaths. *The total number of deaths regardless of cause* - This is the **total mortality count** over a specified period, typically used to calculate the **crude mortality rate** when divided by the population size. - It does not differentiate deaths by **cause** or express them as a **proportion** of the total.

Question 1790: Which study design is primarily used to understand the natural history of a disease?

A. Cohort studies (Correct Answer)
B. Cross-sectional studies
C. Case-control studies
D. Randomized controlled trials

Explanation: ***Cohort studies*** - **Cohort studies** follow a group of individuals over a period, allowing researchers to observe the incidence, progression, and outcomes of a disease naturally. - They are ideal for understanding the **natural history** of a disease, identifying risk factors, and assessing prognosis. - By following subjects from exposure to outcome, cohort studies reveal the temporal sequence and progression patterns of disease. *Cross-sectional studies* - **Cross-sectional studies** assess a population at a single point in time, providing a snapshot of disease prevalence and risk factor distribution. - They cannot establish temporal relationships or the natural progression of a disease because they lack follow-up over time. *Case-control studies* - **Case-control studies** compare individuals with a disease (cases) to individuals without the disease (controls) to identify past exposures or risk factors. - They are retrospective and focus on identifying potential causes of a disease *after* it has occurred, rather than observing its natural development. *Randomized controlled trials* - **Randomized controlled trials (RCTs)** are experimental studies designed to test the efficacy of interventions by randomly assigning participants to treatment or control groups. - They focus on evaluating therapeutic interventions rather than observing the natural, unmodified course of disease.

Practice by Chapter

Principles of Epidemiology

Practice Questions

Measures of Disease Frequency

Practice Questions

Epidemiological Study Designs

Practice Questions

Descriptive Epidemiology

Practice Questions

Analytical Epidemiology

Practice Questions

Experimental Epidemiology

Practice Questions

Screening for Disease

Practice Questions

Surveillance Systems

Practice Questions

Investigation of an Epidemic

Practice Questions

Association and Causation

Practice Questions

Modern Epidemiological Methods

Practice Questions

Critical Appraisal of Epidemiological Studies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free